Table 3 Multivariable adjusted risks of CHD and hard CHD based on different glucose intolerance categories. (n = 408)
| Â | CHD HR (95%CI) | Hard CHD HR (95%CI) | ||||
|---|---|---|---|---|---|---|
E/N | Model 1 | Model 2 | E/N | Model 1 | Model 2 | |
FPG-WHO (mmol/L) | ||||||
  < 6.1 | 156/327 | 1.00 | 1.00 | 41/327 | 1.00 | 1.00 |
 6.1–6.9 | 19/44 | 0.89 (0.55–1.43) | 0.83 (0.51–1.35) | 7/44 | 1.27 (0.57–2.84) | 1.01 (0.44–2.32) |
  ≥ 7 | 27/37 | 1.89 (1.25–2.87) | 1.97 (1.28–3.03) | 10/37 | 2.31 (1.15–4.62) | 2.56 (1.21–5.39) |
FPG-ADA (mmol/L) | ||||||
  < 5.6 | 120/253 | 1.00 | 1.00 | 30/253 | 1.00 | 1.00 |
 5.6–6.9 | 55/118 | 1.04 (0.75–1.43) | 1.02 (0.73–1.41) | 18/118 | 1.39 (0.77–2.49) | 1.30 (0.71–2.40) |
  ≥ 7 | 27/37 | 1.94 (1.27–2.97) | 2.03 (1.30–3.16) | 10/37 | 2.50 (1.22–5.12) | 2.84 (1.31–6.19) |
2Â h-PCPG (mmol/L) | ||||||
  < 7.8 | 112/240 | 1.00 | 1.00 | 31/240 | 1.00 | 1.00 |
 7.8–11.0 | 51/105 | 1.02 (0.73–1.42) | 1.00 (0.70–1.40) | 13/105 | 0.97 (0.51–1.85) | 0.93 (0.47–1.83) |
  ≥ 11 | 39/63 | 1.46 (1.01–2.11) | 1.46 (1.00–2.15) | 14/63 | 1.91 (1.01–3.60) | 1.95 (0.99–3.85) |